Royalty Pharma plc is expected to announce its latest quarterly earnings on Tuesday, May 5th, with a consensus estimate of $1.22 EPS.
In the current trading session, Royalty Pharma plc is priced at $49.75, showing a price increase of 9.91 cents (0.2%) from the previous close. Trading volume is at $394,361, representing a 11.67% increase relative to the average.
The company's previous quarterly earnings report on Tuesday, February 10th, had a consensus estimate of $1.33 EPS.
Royalty Pharma plc offers a forward dividend yield of 1.89%, with a dividend per share of 23.5 cents MRQ and a year-over-year increase of 4.76 cents.
UBS recently upgraded Royalty Pharma plc from "Buy" to "Hold" on April 21, with the price at $49.3 when the new grade was published.
The company's operating cash flow stands at $827.15 million, with a net change in cash of -$320.25 million.
Royalty Pharma plc reported a net income of $214.21 million in the latest period, with an EPS of 64 cents.
Key ratios indicate a strong performance, with a net profit margin of 34.44%, return on equity at 3.31, and a price-earnings ratio of 19.48.
Royalty Pharma plc's total assets amount to $19.62 billion, with total debt at $8.95 billion, resulting in a net debt of $8.33 billion.
This comprehensive update provides investors with essential insights into Royalty Pharma plc's financial status and market performance.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.